BioLine RX BLRX 深 滬
已收盤 12-12 16:00:00 美东时间
3.31
+0.080
+2.48%
華盛通- 最 高3.31
- 今 開3.186
- 成交量 1.09万股
- 最 低 3.141
- 昨 收 3.23
- 總市值 1410.95万
- 52周最高 14.696
- 市盈率 靜 --
- 換手率 0.26%
- 52周最低 2.3001
- 委 比 -79.40%
- 總股本 426.27万
- 歷史最高 4122.00
- 量 比 0.37
- 振 幅 5.23%
- 歷史最低 3.141
- 每 手 1
- 風險率 1.43%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BioLine Rx Q3 EPADS $(0.22) Beats $(1.20) Estimate, Sales $427.000K Miss $990.000K Estimate
BioLine Rx (NASDAQ:BLRX) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(1.20) by 81.67 percent. This is a 214.29 percent decrease over losses of $(0.07) per share from the
11-25 06:36
Earnings Scheduled For November 24, 2025
Companies Reporting Before The Bell • Lotus Technology (NASDAQ:LOT) is likely t...
11-24 19:11
BioLine Rx's Earnings: A Preview
BioLine Rx (NASDAQ:BLRX) is gearing up to announce its quarterly earnings on Mo...
11-21 23:01
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Xenetic Biosciences (NASDAQ:XBIO) stock rose 10.2% to $2.8 during Wedn...
11-20 05:07
BioLineRx Secures USPTO Patent Allowance for Cancer Treatment with GLIX1
Bioline RX Ltd Sponsored ADR ( ($BLRX) ) has provided an update. On November 17...
11-17 20:27
atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression
A study of BPL-003, an intranasal formulation for treatment-resistant depression (TRD), showed significant antidepressant effects with a two-dose regimen (8 mg followed by 12 mg two weeks later). Patients experienced rapid MADRS score reductions, sustained efficacy up to 12 weeks, and improved remission rates. The treatment was well-tolerated, supporting its potential integration into existing psychiatric treatments. Positive results from the Pha...
09-23 11:00
UPDATE: BioLine Rx Q2 EPADS $(1.00) Beats $(1.20) Estimate, Sales $304.000K Miss $924.000K Estimate
BioLine Rx (NASDAQ:BLRX) reported quarterly losses of $(1.00) per share which beat the analyst consensus estimate of $(1.20) by 16.67 percent. The company reported quarterly sales of $304.000 thousand which missed the
08-14 22:12
Earnings Scheduled For August 14, 2025
Companies Reporting Before The Bell • Sunlands Technology (NYSE:STG) is likely ...
08-14 16:32
Examining the Future: BioLine Rx's Earnings Outlook
BioLine Rx (NASDAQ:BLRX) is preparing to release its quarterly earnings on Thur...
08-14 00:02
Where BioLine Rx Stands With Analysts
In the latest quarter, 4 analysts provided ratings for BioLine Rx (NASDAQ:BLRX)...
06-17 20:00
